title: Application of the van nuys prognostic index in a retrospective series of 367 ductal carcinomas in situ of the breast examined by serial macroscopic sectioning: practical considerations.
abstract: The Van Nuys prognostic index (VNPI) was thought to be useful for predicting response to radiotherapy and local recurrence of ductal carcinoma in situ (DCIS). We applied the VNPI under the conditions defined by Silverstein et al., in 367 retrospective DCIS entirely sectioned into serial macroscopic 2 mm slices (155 patients had radiotherapy, median follow-up 71 months). The percentage of positive blocks with DCIS was also estimated for each specimen with cut-offs at 30% and 60% to obtain three scores. One hundred and ninety five lesions had a low VNPI, 152 an intermediate VNPI, and 20 a high VNPI. There were 9% of local recurrences (half invasive, all in the group without radiotherapy) in the low VNPI group. The local recurrence rate increased with size (p = 0.001), with reduction of distance to margins (p = 0.05), with histologic grade (p = 0.02), with percentage of positive blocks (p = 0.0003) and with VNPI score (p = 0.03). The percentage of positive blocks was the only independent predictor for local recurrence (p = 0.0001).
  
  
  CONCLUSIONS
  (1) The VNPI was a local recurrence rate predictor between the low and the intermediate groups but in our series the low VNPI group had a surprisingly high local recurrence rate. (2) Only prospective studies will assess the importance of margin width and the role of radiotherapy in maintaining local control. (3) Estimation of the percentage of positive blocks is simple, may be an alternative when measurement of DCIS is difficult and should be taken into account.
authors.affiliation: Department of Pathology, Institut Bergonié, Bordeaux, France. lepolles@bergonie.org
authors.forename: I
authors.initials: I
authors.lastname: de Mascarel
authors.forename: F
authors.initials: F
authors.lastname: Bonichon
authors.forename: G
authors.initials: G
authors.lastname: MacGrogan
authors.forename: C T
authors.initials: CT
authors.lastname: de Lara
authors.forename: A
authors.initials: A
authors.lastname: Avril
authors.forename: V
authors.initials: V
authors.lastname: Picot
authors.forename: M
authors.initials: M
authors.lastname: Durand
authors.forename: L
authors.initials: L
authors.lastname: Mauriac
authors.forename: M
authors.initials: M
authors.lastname: Trojani
authors.forename: J M
authors.initials: JM
authors.lastname: Coindre
mesh_terms: D001943:Breast Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000473:pathology* / Q000532:radiotherapy / Q000601:surgery; D018270:Carcinoma, Ductal, Breast / Q000453:epidemiology; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000175:diagnosis / Q000401:mortality / Q000473:pathology* / Q000532:radiotherapy / Q000601:surgery; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015993:Life Tables; D015412:Mastectomy, Segmental; D008867:Microtomy / Q000379:methods* / Q000706:statistics & numerical data; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D011379:Prognosis; D016016:Proportional Hazards Models; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D012720:Severity of Illness Index; D016019:Survival Analysis; D016896:Treatment Outcome